334 related articles for article (PubMed ID: 16446383)
1. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.
Radomska HS; Bassères DS; Zheng R; Zhang P; Dayaram T; Yamamoto Y; Sternberg DW; Lokker N; Giese NA; Bohlander SK; Schnittger S; Delmotte MH; Davis RJ; Small D; Hiddemann W; Gilliland DG; Tenen DG
J Exp Med; 2006 Feb; 203(2):371-81. PubMed ID: 16446383
[TBL] [Abstract][Full Text] [Related]
2. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα.
Radomska HS; Alberich-Jordà M; Will B; Gonzalez D; Delwel R; Tenen DG
J Clin Invest; 2012 Aug; 122(8):2955-66. PubMed ID: 22797303
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of serine 21 modulates the proliferation inhibitory more than the differentiation inducing effects of C/EBPα in K562 cells.
Fragliasso V; Chiodo Y; Ferrari-Amorotti G; Soliera AR; Manzotti G; Cattelani S; Candini O; Grisendi G; Vergalli J; Mariani SA; Guerzoni C; Calabretta B
J Cell Biochem; 2012 May; 113(5):1704-13. PubMed ID: 22212957
[TBL] [Abstract][Full Text] [Related]
4. Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
Nishioka C; Ikezoe T; Yang J; Takeshita A; Taniguchi A; Komatsu N; Togitani K; Koeffler HP; Yokoyama A
Leuk Res; 2008 Jun; 32(6):865-72. PubMed ID: 17983653
[TBL] [Abstract][Full Text] [Related]
5. C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia.
Sabatier M; Birsen R; Lauture L; Mouche S; Angelino P; Dehairs J; Goupille L; Boussaid I; Heiblig M; Boet E; Sahal A; Saland E; Santos JC; Armengol M; Fernández-Serrano M; Farge T; Cognet G; Simonetta F; Pignon C; Graffeuil A; Mazzotti C; Avet-Loiseau H; Delos O; Bertrand-Michel J; Chedru A; Dembitz V; Gallipoli P; Anstee NS; Loo S; Wei AH; Carroll M; Goubard A; Castellano R; Collette Y; Vergez F; Mansat-De Mas V; Bertoli S; Tavitian S; Picard M; Récher C; Bourges-Abella N; Granat F; Kosmider O; Sujobert P; Colsch B; Joffre C; Stuani L; Swinnen JV; Guillou H; Roué G; Hakim N; Dejean AS; Tsantoulis P; Larrue C; Bouscary D; Tamburini J; Sarry JE
Cancer Discov; 2023 Jul; 13(7):1720-1747. PubMed ID: 37012202
[TBL] [Abstract][Full Text] [Related]
6. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression.
Zheng R; Friedman AD; Levis M; Li L; Weir EG; Small D
Blood; 2004 Mar; 103(5):1883-90. PubMed ID: 14592841
[TBL] [Abstract][Full Text] [Related]
7. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
[TBL] [Abstract][Full Text] [Related]
8. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
9. Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Hu X; Chen F
Hematology; 2019 Dec; 24(1):651-660. PubMed ID: 31533545
[No Abstract] [Full Text] [Related]
10. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.
Yang X; Sexauer A; Levis M
Br J Haematol; 2014 Jan; 164(1):61-72. PubMed ID: 24116827
[TBL] [Abstract][Full Text] [Related]
11. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
Sexauer A; Perl A; Yang X; Borowitz M; Gocke C; Rajkhowa T; Thiede C; Frattini M; Nybakken GE; Pratz K; Karp J; Smith BD; Levis M
Blood; 2012 Nov; 120(20):4205-14. PubMed ID: 23012328
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in
Zhang W; Ly C; Ishizawa J; Mu H; Ruvolo V; Shacham S; Daver N; Andreeff M
Haematologica; 2018 Oct; 103(10):1642-1653. PubMed ID: 29773601
[TBL] [Abstract][Full Text] [Related]
13. Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML.
Pulikkan JA; Dengler V; Peer Zada AA; Kawasaki A; Geletu M; Pasalic Z; Bohlander SK; Ryo A; Tenen DG; Behre G
Leukemia; 2010 May; 24(5):914-23. PubMed ID: 20376080
[TBL] [Abstract][Full Text] [Related]
14. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.
Liu S; Yin L; Stroopinsky D; Rajabi H; Puissant A; Stegmaier K; Avigan D; Kharbanda S; Kufe D; Stone R
Blood; 2014 Jan; 123(5):734-42. PubMed ID: 24282218
[TBL] [Abstract][Full Text] [Related]
15. E6AP, an E3 ubiquitin ligase negatively regulates granulopoiesis by targeting transcription factor C/EBPα for ubiquitin-mediated proteasome degradation.
Pal P; Lochab S; Kanaujiya JK; Kapoor I; Sanyal S; Behre G; Trivedi AK
Cell Death Dis; 2013 Apr; 4(4):e590. PubMed ID: 23598402
[TBL] [Abstract][Full Text] [Related]
16. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene.
Asou H; Gombart AF; Takeuchi S; Tanaka H; Tanioka M; Matsui H; Kimura A; Inaba T; Koeffler HP
Genes Chromosomes Cancer; 2003 Feb; 36(2):167-74. PubMed ID: 12508245
[TBL] [Abstract][Full Text] [Related]
17. The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.
Odgerel T; Kikuchi J; Wada T; Shimizu R; Futaki K; Kano Y; Furukawa Y
Oncogene; 2008 May; 27(22):3102-10. PubMed ID: 18071308
[TBL] [Abstract][Full Text] [Related]
18. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.
Schwäble J; Choudhary C; Thiede C; Tickenbrock L; Sargin B; Steur C; Rehage M; Rudat A; Brandts C; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 Mar; 105(5):2107-14. PubMed ID: 15536149
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.
Akiyama H; Umezawa Y; Ishida S; Okada K; Nogami A; Miura O
Cancer Lett; 2019 Jul; 453():84-94. PubMed ID: 30946869
[TBL] [Abstract][Full Text] [Related]
20. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]